Cutter Capital Management as of March 31, 2024
Portfolio Holdings for Cutter Capital Management
Cutter Capital Management holds 26 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 9.3 | $24M | 447k | 54.23 | |
| Gilead Sciences (GILD) | 7.4 | $19M | 265k | 73.25 | |
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 6.1 | $16M | 1.1M | 14.11 | |
| Regeneron Pharmaceuticals (REGN) | 6.0 | $16M | 16k | 962.49 | |
| BioMarin Pharmaceutical (BMRN) | 5.8 | $15M | 175k | 87.34 | |
| Ionis Pharmaceuticals (IONS) | 4.8 | $13M | 289k | 43.35 | |
| Royalty Pharma Shs Class A (RPRX) | 4.8 | $13M | 412k | 30.37 | |
| Sarepta Therapeutics (SRPT) | 4.7 | $12M | 94k | 129.46 | |
| ACADIA Pharmaceuticals (ACAD) | 4.7 | $12M | 658k | 18.49 | |
| Biogen Idec (BIIB) | 4.3 | $11M | 52k | 215.63 | |
| BioCryst Pharmaceuticals (BCRX) | 4.1 | $11M | 2.1M | 5.08 | |
| Halozyme Therapeutics (HALO) | 4.0 | $10M | 255k | 40.68 | |
| Perrigo SHS (PRGO) | 4.0 | $10M | 322k | 32.19 | |
| Exelixis (EXEL) | 3.6 | $9.5M | 399k | 23.73 | |
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 3.5 | $9.2M | 542k | 16.89 | |
| Eli Lilly & Co. (LLY) | 3.3 | $8.6M | 11k | 777.96 | |
| Agios Pharmaceuticals (AGIO) | 3.2 | $8.4M | 289k | 29.24 | |
| Crispr Therapeutics Namen Akt (CRSP) | 3.1 | $8.2M | 120k | 68.16 | |
| Arcellx Common Stock (ACLX) | 2.8 | $7.4M | 107k | 69.55 | |
| Insmed Com Par $.01 (INSM) | 2.4 | $6.2M | 227k | 27.13 | |
| Miragen Therapeutics (VRDN) | 1.9 | $4.9M | 279k | 17.51 | |
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.7 | $4.5M | 80k | 56.09 | |
| Kyverna Therapeutics (KYTX) | 1.6 | $4.1M | 167k | 24.84 | |
| Pliant Therapeutics (PLRX) | 1.1 | $2.9M | 194k | 14.90 | |
| Cabaletta Bio (CABA) | 1.0 | $2.7M | 158k | 17.06 | |
| Ironwood Pharmaceuticals Com Cl A Call Option (IRWD) | 0.8 | $2.2M | 250k | 8.71 |
